Merck KGaA to acquire Bio-Techne for $73/share in $11.3B deal

BIO-TECHNE Corp

Purchase price $73/share in cash; enterprise value $11.3B (EUR 9.9B); 36% premium to 1-month VWAP.
Expected to close by late 2026 / early 2027, subject to shareholder and regulatory approvals.
Annual cost synergies of ~EUR 140M expected fully realized by year 3 post-close.
Bio-Techne FY2025 net sales >$1.2B; ~3,000 employees; to operate as part of Merck KGaA Life Science.
Transaction approved by Bio-Techne Board and Merck corporate bodies; debt-funded with investment-grade credit maintained.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.